Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
By Andrew P. Feinberg, M. Koldobskiy, A. Göndör. Nature reviews genetics, 2016
773 citations recorded by the source corpus.
This year is the tenth anniversary of the publication in this journal of a model suggesting the existence of 'tumour progenitor genes'. These genes are epigenetically disrupted at the earliest stages of malignancies, even before mutations, and thus cause altered differentiation throughout tumour evolution. The past decade of discovery in cancer epigenetics has revealed a number of similarities between cancer genes and stem cell reprogramming genes, widespread mutations in epigenetic regulators, and the part played by chromatin structure in cellular plasticity in both development and cancer. In the light of these discoveries, we suggest here a framework for cancer epigenetics involving three types of genes: 'epigenetic mediators', corresponding to the tumour progenitor genes suggested earlier; 'epigenetic modifiers' of the mediators, which are frequently mutated in cancer; and 'epigenetic modulators' upstream of the modifiers, which are responsive to changes in the cellular environment and often linked to the nuclear architecture. We suggest that this classification is helpful in framing new diagnostic and therapeutic approaches to cancer.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/022794a5c10a3bc670c418a072fec5c4bf3c8a31
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Combination therapy in combating cancer (2017, background): “Mutations in the enzymes that regulate the epigenome can potentially lead to cancer-like states because of their ability to create gross effects [92].”
- Genetics and biology of prostate cancer (2018, background): “…and hydroxymethylation), histone modification, or nucleosome remodeling can drive tumorigenesis in many cancer types (Dawson and Kouzarides 2012; Feinberg et al. 2016; Flavahan et al. 2017; Genovese et al. 2017), including prostate cancer (Albany et al. 2011; Jeronimo et al. 2011;…”